Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 11/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL54119 | 0.81 | KDM4E (0.52) | BCAT2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL29468958 | 0.81 | KDM4E (0.52) | BCAT2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL466296 | 0.80 | KDM4E (0.54) | BCAT2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL31255754 | 0.80 | PARP1 (0.34) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL3034247 | 0.80 | PARP1 (0.38) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL29956608 | 0.78 | PARP1 (0.41) | BCAT2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL402013 | 0.76 | BCAT2 (0.56) | BCAT2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL2540273 | 0.75 | PARP1 (0.46) | BCAT2KDM4EALDH1A1MAPTHPGD | |
| Alcohol SCHEMBL29246862 | 0.74 | BCAT2 (0.50) | BCAT2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL6066755 | 0.74 | KDM4E (0.48) | BCAT2KDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | BCAT2 372/4885KDM4E 2606/4885ALDH1A1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.